Straumann Holding AG (SAUHY) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Straumann Holding AG (SAUHY) Healthcare & Pipeline Overview

Straumann Holding AG, a Swiss-based company, is a global leader in the dental implant and orthodontic solutions market, offering a comprehensive portfolio of implant systems, CADCAM prosthetics, and clear aligners. With a strong international presence and a focus on innovation, Straumann serves a diverse range of clinical needs and patient segments.

What Is the Investment Thesis for SAUHY?

Straumann Holding AG presents a notable research candidate due to its leading position in the growing dental implant and orthodontic solutions market. The company's strong brand reputation, diverse product portfolio, and global reach provide a solid foundation for continued growth. With a P/E ratio of 45.5 and a profit margin of 13.7%, Straumann demonstrates financial stability and profitability. Key growth catalysts include the increasing demand for dental aesthetics, the aging global population, and the expansion of digital dentistry solutions. The company's commitment to innovation and strategic acquisitions further strengthens its competitive advantage. However, potential risks include regulatory changes, competition from established and emerging players, and economic downturns affecting discretionary healthcare spending.

Based on FMP financials and quantitative analysis

SAUHY Key Highlights

Market Cap of $19.1B reflects Straumann's strong position in the dental solutions market.

• P/E ratio of 45.5 indicates investor confidence in Straumann's earnings potential.
• Gross Margin of 70.1% demonstrates efficient cost management and premium pricing power.
• ROE of 17.0% highlights Straumann's effective utilization of equity to generate profits.
• Debt-to-Equity ratio of 19.35 indicates a conservative capital structure and manageable debt levels.

Who Are SAUHY's Competitors?

SAUHY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SAUHY's Key Strengths?

Global market leader in dental implants.

• Strong brand reputation and customer loyalty.
• Comprehensive product portfolio.
• Extensive distribution network.

What Are SAUHY's Weaknesses?

High price point compared to some competitors.

• Dependence on developed markets.
• Exposure to currency fluctuations.

What Could Drive SAUHY Stock Higher?

Increasing demand for dental implants and orthodontic solutions due to an aging global population.

• Expansion of digital dentistry and clear aligner therapy markets.
• Potential regulatory approvals for new products and technologies.
• Strategic acquisitions to expand product portfolio and geographic reach.
• Continued investment in research and development to drive innovation.

What Are the Key Risks for SAUHY?

Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.

• Rich valuation — a P/E of 45.5 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
• Intense competition from established and emerging players.
• Regulatory changes and compliance requirements.
• Economic downturns affecting discretionary healthcare spending.
• Technological disruptions in the dental industry.
• Currency fluctuations affecting international sales and profitability.

What Are the Growth Opportunities for SAUHY?

• Expansion in Emerging Markets: Straumann has a significant opportunity to expand its presence in emerging markets, particularly in Asia Pacific and Latin America. These regions are experiencing rapid economic growth and increasing demand for advanced dental solutions. By leveraging its existing distribution network and tailoring its product offerings to local market needs, Straumann can capture a larger share of these high-growth markets. This expansion could contribute significantly to revenue growth over the next 3-5 years.
• Digital Dentistry Solutions: The increasing adoption of digital dentistry presents a significant growth opportunity for Straumann. The company's portfolio of intra-oral scanners, milling machines, and 3D printers enables dental professionals to streamline their workflows and improve treatment outcomes. By investing in research and development and expanding its digital solutions offerings, Straumann can capitalize on this growing trend and strengthen its competitive advantage. The digital dentistry market is expected to grow at a CAGR of 10-15% over the next 5 years.
• Clear Aligner Therapy: Straumann's ClearCorrect business offers significant growth potential in the rapidly expanding clear aligner therapy market. Clear aligners are becoming increasingly popular among patients seeking a discreet and convenient alternative to traditional braces. By investing in marketing and expanding its ClearCorrect product line, Straumann can capture a larger share of this growing market. The clear aligner market is projected to reach $5 billion by 2028.
• Strategic Acquisitions: Straumann has a history of successful acquisitions that have expanded its product portfolio and geographic reach. The company can continue to pursue strategic acquisitions to further strengthen its competitive position and accelerate growth. Potential acquisition targets include companies with complementary technologies, products, or distribution networks. These acquisitions can provide access to new markets, technologies, and customer segments.
• Regenerative Solutions: Straumann's regenerative solutions for tooth preservation, implant-site management, and implant preservation represent a significant growth opportunity. As the focus on preventative dentistry increases, the demand for regenerative solutions is expected to grow. By investing in research and development and expanding its regenerative solutions portfolio, Straumann can capitalize on this growing trend and improve patient outcomes. The regenerative dentistry market is projected to grow at a CAGR of 8-10% over the next 5 years.

What Are SAUHY's Competitive Advantages?

• Strong brand reputation and established market leadership in the dental implant market.
• Comprehensive product portfolio covering a wide range of dental solutions.
• Extensive global distribution network with a strong presence in key markets.
• Commitment to innovation and research and development.
• High switching costs for dental professionals due to training and familiarity with Straumann products.

What Does SAUHY Do?

Founded in 1954 and headquartered in Basel, Switzerland, Straumann Holding AG has evolved into a global leader in tooth replacement and orthodontic solutions. The company operates through five segments: Sales Europe, Middle East and Africa; Sales North America; Sales Asia Pacific; Sales Latin America; and Operations. Straumann's comprehensive product portfolio includes dental implants, instruments, CADCAM prosthetics, orthodontic and clear aligners, biomaterials, and digital equipment and solutions. These products are used in tooth correction, replacement, restoration, and prevention of tooth loss. Straumann offers a wide array of implant systems, components, and related instruments, as well as healing components, materials and surfaces, surgical sets and instruments, and guided surgery and navigation products. The company also provides prosthetics, including angled solutions, connections, components, and molar solutions. Straumann's digital solutions encompass intra-oral and lab scanners, milling machines, dynamic navigation systems, and 3D printers, along with consumables like blocks, discs, resins, titanium bases, and abutment blanks. The company sells its products under the Straumann, Neodent, Medentika, Anthogyr, ClearCorrect, NUVO, and other brands through a network of distribution subsidiaries and partners, and third-party distributors, as well as through its e-shop. Straumann serves clinicals needs, patient segments, and healthcare systems across the globe.

What Products and Services Does SAUHY Offer?

• Develops and manufactures dental implants for tooth replacement.
• Offers CADCAM prosthetics for customized dental restorations.
• Provides orthodontic solutions, including clear aligners, for teeth straightening.
• Manufactures biomaterials for bone and tissue regeneration.
• Offers digital equipment and solutions, such as intra-oral scanners and 3D printers.
• Provides instruments and surgical sets for dental procedures.
• Offers online education and training for dental professionals.

How Does SAUHY Make Money?

• Sells dental implants, prosthetics, and orthodontic solutions to dental professionals and institutions.
• Generates revenue through a network of distribution subsidiaries, partners, and third-party distributors.
• Offers digital equipment and solutions with recurring revenue streams from consumables and software licenses.

What Industry Does SAUHY Operate In?

Straumann Holding AG operates in the medical instruments and supplies industry, which is experiencing steady growth driven by an aging global population, increasing demand for cosmetic dentistry, and technological advancements in dental solutions. The market is competitive, with key players focusing on innovation, product differentiation, and geographic expansion. Straumann's strong brand reputation, comprehensive product portfolio, and global distribution network position it favorably within this landscape. The increasing adoption of digital dentistry and clear aligner therapies presents significant growth opportunities for companies like Straumann.

Who Are SAUHY's Key Customers?

• Dental professionals, including dentists, orthodontists, and oral surgeons.
• Dental clinics and hospitals.
• Dental laboratories.

Wall Street analysts project Straumann Holding AG revenue of about $2.71B for fiscal 2026, with EPS near $0.31.

Straumann Holding AG has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 10.1% below estimates on average.

Straumann Holding AG's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 9.35 places it in the safe zone, indicating low near-term bankruptcy risk.

Return on equity for Straumann Holding AG stands at 16.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 9.3%, showing how much profit it generates from its asset base. SAUHY trades at a trailing price-to-earnings ratio of 45.47, above the Healthcare sector average of ~23x. Its free cash flow yield is 2.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.21 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.2%, the inverse of the P/E and a quick read on earnings relative to price.

Straumann Holding AG (SAUHY) Valuation Context

Valued at $19.1B, SAUHY is classified as a large-cap stock. Relative to its peer group, SAUHY's quantitative score of 48/100 is roughly in line with the peer average of 55/100.

SAUHY Revenue & Earnings Trend

In Q2 2026, SAUHY generated $1.41B in top-line revenue, marking a sequential increase of 13.1%. The company recorded net income of $255.1M, with diluted EPS of $0.16. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, SAUHY averaged $0.13 in diluted EPS.

Company Profile

Straumann Holding AG operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Basel, CH. The company is led by CEO Guillaume Daniellot. SAUHY has traded publicly since 2014.

SAUHY Financials

SAUHY Latest News

SAUHY Analyst Consensus

SAUHY MoonshotScore

SAUHY Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources